Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
Active & Responsive
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: Nashville TN, Oklahoma City OK, Huntersville NC,
Sponsor: Phanes Therapeutics
Sex: All
Age: 18+
Code: NCT05431270
Phase1, Phase2, Recruiting
Active & Responsive
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
for
Non-Small Cell Lung Cancer, NSCLC,
Location: Nashville TN, Charlotte NC, Fairfax VA, Houston TX,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT06043817
Phase1, Phase2, Recruiting
Active & Responsive
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
for
Metastatic Hepatocellular Carcinoma,
Location: Nashville TN, Zion IL, Pittsburgh PA, Houston TX,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06427941
Phase1, Phase2, Recruiting
Active & Responsive
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
for
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms,
Location: Nashville TN, Centerville OH, Urbana IL, Detroit MI,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05386108
Phase1, Phase2, Recruiting
Active & Responsive
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
for
Breast Neoplasms, Breast Cancer
Location: Nashville TN, Skokie IL, Norfolk VA, Dallas TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06797635
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
for
Lymphoma, Non-Hodgkin, B-cell Lymphoma,
Location: Nashville TN, Chicago IL, Ann Arbor MI, Iowa City IA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07101328
Phase1, Recruiting
Active & Responsive
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
for
HR+ HER2- Breast Cancer
Location: Nashville TN, Austin TX, San Antonio TX, Lone Tree CO,
Sponsor: Faeth Therapeutics
Sex: All
Age: 18+
Code: NCT07558733
Phase1, Phase2, Recruiting
Active & Responsive
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Location: Nashville TN, Grand Rapids MI, East Brunswick NJ,
Sponsor: Duboce Biopharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07705035
Phase1, Recruiting
Active & Responsive
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Location: Nashville TN, Fairfax VA, Dallas TX, Houston TX,
Sponsor: NEOK Bio, Inc.
Sex: All
Age: 18+
Code: NCT07612176
Phase1, Recruiting
Active & Responsive
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
for
Extensive Stage-small Cell Lung Cancer
Location: Nashville TN, Birmingham AL, Chicago IL, Milwaukee WI,
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT06362252
Phase1, Phase2, Recruiting
Active & Responsive
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for
Prostate Cancer, Prostatic Neoplasms
Location: Nashville TN, Lexington KY, Memphis TN, Atlanta GA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Male
Age: 18+
Code: NCT06925737
Phase3, Recruiting
Active & Responsive
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies